Richard Aviv, MD, PhD
SPECIALTY AND TITLE
The Ottawa Hospital
University of Ottawa
AREA OF RESEARCH
My career goals are to 1) advance precision medicine through imaging biomarker discovery and application, 2) to tailor existing and new therapeutic strategies to imaging selected patient populations and 3) to monitor disease progression based on these biomarkers.
MAJOR CONTRIBUTIONS TO SCIENCE AND/OR HEALTH CARE DELIVER
I was first to describe the CTA-Spot Sign which is a potent marker of hematoma expansion in Intracranial hemorrhage, contributed to STOP-IT, SPOTLIGHT and STOP-AUST studies examining the utility of medical therapeutic intervention in Spot Sign selected patients. Through the PREDICT study group I have systematically studied CTA Spot sign prevalence, bleeding rates, described the interaction between scan acquisition and time with bleeding rate, assessed optimal features determining expansion risk within a clinical score, documented the interobserver agreement within a multicenter initiative and prospectively validated CTA Spot sign significance in 2 multicenter studies.
Over the past few years, I have applied my understanding of perfusion and graph theory to Multiple sclerosis as a surrogate of cortical integrity. I have received several grants evaluating the relationship between cortical perfusion and cognition. Our published work demonstrated an association between reduced cortical perfusion and impaired cognition